Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $3.10 billion. The enterprise value is $1.88 billion.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 93.68 million shares outstanding. The number of shares has increased by 37.21% in one year.
| Current Share Class | 93.68M |
| Shares Outstanding | 93.68M |
| Shares Change (YoY) | +37.21% |
| Shares Change (QoQ) | +1.76% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 111.24% |
| Float | 92.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,077.55 |
| Forward PS | 292.90 |
| PB Ratio | 2.47 |
| P/TBV Ratio | 2.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2,467.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.53, with a Debt / Equity ratio of 0.04.
| Current Ratio | 22.53 |
| Quick Ratio | 22.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.84% and return on invested capital (ROIC) is -21.10%.
| Return on Equity (ROE) | -30.84% |
| Return on Assets (ROA) | -20.13% |
| Return on Invested Capital (ROIC) | -21.10% |
| Return on Capital Employed (ROCE) | -28.89% |
| Revenue Per Employee | $1,739 |
| Profits Per Employee | -$751,149 |
| Employee Count | 437 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.06% in the last 52 weeks. The beta is 0.28, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | -26.06% |
| 50-Day Moving Average | 30.99 |
| 200-Day Moving Average | 43.73 |
| Relative Strength Index (RSI) | 58.46 |
| Average Volume (20 Days) | 797,068 |
Short Selling Information
The latest short interest is 10.16 million, so 10.85% of the outstanding shares have been sold short.
| Short Interest | 10.16M |
| Short Previous Month | 9.84M |
| Short % of Shares Out | 10.85% |
| Short % of Float | 11.01% |
| Short Ratio (days to cover) | 11.75 |
Income Statement
In the last 12 months, CRNX had revenue of $760,000 and -$328.25 million in losses. Loss per share was -$3.82.
| Revenue | 760,000 |
| Gross Profit | -262.30M |
| Operating Income | -376.73M |
| Pretax Income | -258.54M |
| Net Income | -328.25M |
| EBITDA | -373.49M |
| EBIT | -376.73M |
| Loss Per Share | -$3.82 |
Full Income StatementBalance Sheet
The company has $1.27 billion in cash and $50.82 million in debt, giving a net cash position of $1.22 billion or $13.06 per share.
| Cash & Cash Equivalents | 1.27B |
| Total Debt | 50.82M |
| Net Cash | 1.22B |
| Net Cash Per Share | $13.06 |
| Equity (Book Value) | 1.25B |
| Book Value Per Share | 13.41 |
| Working Capital | 1.23B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$261.57 million and capital expenditures -$3.75 million, giving a free cash flow of -$265.32 million.
| Operating Cash Flow | -261.57M |
| Capital Expenditures | -3.75M |
| Free Cash Flow | -265.32M |
| FCF Per Share | -$2.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -49,569.74% |
| Pretax Margin | -43,191.05% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.21% |
| Shareholder Yield | -37.21% |
| Earnings Yield | -10.59% |
| FCF Yield | -8.56% |
Analyst Forecast
The average price target for CRNX is $75.00, which is 126.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $75.00 |
| Price Target Difference | 126.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 309.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 21.89 and a Piotroski F-Score of 2.
| Altman Z-Score | 21.89 |
| Piotroski F-Score | 2 |